A TREM2 antibody energizes microglia

Loss-of-function variants of TREM2 increase risk for Alzheimer's disease. A new study presents a therapeutic candidate — ATV:TREM2, a TREM2-activating antibody engineered with a transferrin receptor binding site to facilitate blood-to-brain transport. Treatment of a mouse model of Alzheimer's disease with ATV:TREM2 improved energy metabolism and microglial function.